Drug intelligence / Profile preview

Fupu Ganmao Granules

Development stage: Phase 2
Lead developer: Zhejiang Tianyitang Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Fupu Ganmao Granules (芙朴感冒颗粒) is a Traditional Chinese Medicine (TCM) formulation developed by Zhejiang Tianyitang Pharmaceutical for the treatment of influenza, specifically targeting the 'wind-heat attacking the exterior' syndrome. As a botanical-based therapy, it is composed of multiple herbal extracts intended to alleviate symptoms such as fever, sore throat, and cough associated with viral respiratory infections. The drug is currently being evaluated in a multicenter Phase II clinical trial (CTR20254989) in China to explore its efficacy, safety, and optimal dosing for influenza patients.

Brand names: Fupu Ganmao Granules
Other names: 芙朴感冒颗粒

Beyond the preview

Go deeper on Fupu Ganmao Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fupu Ganmao Granules.